1. Home
  2. ADPT

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Founded: 2009 Country:
United States
United States
Employees: N/A City: SEATTLE
Market Cap: 514.3M IPO Year: 2019
Target Price: $6.80 AVG Volume (30 days): 1.7M
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.49 EPS Growth: N/A
52 Week Low/High: $2.28 - $9.08 Next Earning Date: 05-07-2024
Revenue: $174,502,000 Revenue Growth: -5.33%
Revenue Growth (this year): 5.32% Revenue Growth (next year): 25.66%

ADPT Daily Stock ML Predictions

Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
PETERSON TYCHO ADPT Chief Financial Officer Mar 4 '24 Sell $3.44 15,456 $53,168.64 531,553 SEC Form 4
ROBINS CHAD M ADPT CEO and Chairman Mar 4 '24 Sell $3.44 5,879 $20,223.76 2,619,495 SEC Form 4
ROBINS CHAD M ADPT CEO and Chairman Mar 4 '24 Sell $3.43 42,794 $146,783.42 2,576,701 SEC Form 4
BOBULSKY SUSAN ADPT Chief Commercial Officer, MRD Mar 4 '24 Sell $3.43 6,016 $20,634.88 255,265 SEC Form 4
BOBULSKY SUSAN ADPT Chief Commercial Officer, MRD Mar 4 '24 Sell $3.44 6,975 $23,994.00 248,290 SEC Form 4
PISKEL KYLE ADPT Principal Accounting Officer Nov 16 '23 Sell $4.13 259 $1,069.67 87,305 SEC Form 4

Share on Social Networks: